What is the appropriate pre‑operative management for an elderly patient with type 2 diabetes mellitus on basal insulin glargine undergoing MRCP or surgery?

Pre-operative Management of Elderly Type 2 Diabetes Patient on Insulin Glargine

For an elderly patient with type 2 diabetes on basal insulin glargine undergoing MRCP or surgery, administer 75-80% of the usual evening glargine dose the night before the procedure, monitor blood glucose every 2-4 hours while NPO, and use short-acting insulin for correction as needed. 1

Key Pre-operative Steps

Insulin Glargine Dosing

• Give 75-80% of the patient's usual glargine dose the evening before surgery 1, 2
• This specific dosing achieves optimal perioperative glucose control with lower hypoglycemia risk compared to full dosing 3
• Research demonstrates that patients receiving 60-87% of their usual dose (mean 73-75%) had the highest proportion (78%) achieving target glucose range 3
• A 25% dose reduction the evening before surgery improves target range achievement while decreasing hypoglycemia risk 4, 1

Blood Glucose Targets

• Target perioperative glucose: 100-180 mg/dL 1, 2
• Tighter targets (<80-180 mg/dL) do not improve outcomes and increase hypoglycemia 1
• For elderly patients specifically, conservative dosing is critical as hypoglycemia may be difficult to recognize 5

Monitoring Protocol

• Monitor blood glucose every 2-4 hours while NPO 1, 2, 6
• Use short- or rapid-acting insulin for correction when glucose exceeds target 1
• More frequent monitoring (every 2-4 hours) is preferred over older recommendations of every 4-6 hours [1 vs 4]

Additional Pre-operative Considerations

Risk Assessment

Perform pre-operative cardiac risk assessment in elderly patients, particularly those with:

• High risk for ischemic heart disease
• Autonomic neuropathy
• Renal failure 1, 2

Medication Management

• Hold metformin on the day of surgery 1, 2
• Discontinue SGLT2 inhibitors 3-4 days before surgery 1, 2, 6
• Hold other oral glucose-lowering agents the morning of surgery 1

Elderly-Specific Precautions

The FDA label emphasizes that elderly patients require conservative dosing to avoid hypoglycemic reactions, as hypoglycemia may be difficult to recognize in this population 5. This makes the 75-80% dosing recommendation particularly appropriate rather than more aggressive reductions.

Renal and Hepatic Considerations

For elderly patients with renal or hepatic impairment:

• Frequent glucose monitoring is essential
• Dosage adjustments may be necessary
• Insulin clearance may be altered 5

Post-operative Management

Once the patient resumes eating:

• Implement basal-bolus insulin regimen (basal glargine plus premeal short/rapid-acting insulin) 1, 7
• This approach improves glycemic control and reduces complications compared to sliding scale insulin alone 7
• Continue monitoring every 2-4 hours initially, then adjust frequency based on stability

Common Pitfalls to Avoid

1. Do not use sliding scale insulin alone - This reactive approach increases complications compared to basal-bolus regimens 7
2. Do not give full glargine dose - Full dosing increases hypoglycemia risk without improving outcomes 3
3. Do not target glucose <100 mg/dL - Overly tight control increases hypoglycemia without benefit 1
4. Do not reduce monitoring frequency prematurely - Elderly patients need close observation for unrecognized hypoglycemia 5

For MRCP Specifically

Since MRCP is typically a shorter, non-invasive procedure:

• Same insulin dosing principles apply (75-80% of usual glargine dose)
• Ensure glucose infusion if prolonged NPO status and patient normally takes morning insulin
• May not require the same intensive post-procedure monitoring as major surgery unless complications arise

The evidence strongly supports this structured approach, with the most recent ADA guidelines 1, 2 providing the clearest recommendations, supported by research demonstrating improved outcomes with the 75-80% dosing strategy 3 and basal-bolus regimens over sliding scale approaches 7.